Patents by Inventor Johnson Varghese

Johnson Varghese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTRIIB ligand trap compositions and uses thereof
    Patent number: 12186370
    Abstract: The present application relates to recombinant fusion proteins consisting of the extracellular domain (ECD) of human activin receptor IIB (ActRIIB) linked to a constant domain of an immunoglobulin, wherein the protein acts as an ActRIIB ligand trap, and compositions of the same comprising particular sequence variants. The present application further relates to method of making such recombinant fusion proteins and uses of such recombinant fusion proteins in the treatment of various diseases.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: January 7, 2025
    Assignee: Celgene Corporation
    Inventors: Johnson Varghese, David Mahon, Nandakumar Madayiputhiya, Kendall Davis Carey, Promod Kumar Mehndiratta, Ping Carlson, Rajeev Boregowda
  • Methods for processing coagulation factors
    Patent number: 9598687
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 21, 2017
    Assignee: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese
  • METHODS FOR PROCESSING COAGULATION FACTORS
    Publication number: 20140303353
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Application
    Filed: August 31, 2012
    Publication date: October 9, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese